Platform Technologies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Platform Technologies
The standardization of upstream and downstream bioprocessing is growing, but several kinks need to be ironed out.


Pharmaceutical Technology
Volume 36, Issue 3, pp. 46-50


(IMAGE: GREGOR SCHUSTER/PHOTOGRAPHER'S CHOICE RF/GETTY IMAGES)
Platform technology is becoming a popular industry approach for bioprocessing, but just how are companies using it? Pharmaceutical Technology talked to industry experts to gain insight: Morrey Atkinson, PhD, CSO and vice-president of R&D and Drug-Substance Manufacturing at Cook Pharmica; Peter Moesta, PhD, senior vice-president of Biologics Manufacturing and Process Development at Bristol-Myers Squibb; and Jim Powell, business development manager at Ashai Kasei Bioprocess.

PharmTech: How might platform technologies be applied to upstream and downstream processes? Is one easier than the other?

Atkinson (Cook): It is not easier to develop platforms for either upstream or downstream, it is just different. The main difference in developing platform processes for either is that, in most cases, one develops upstream processes for the cell line and the expression system, while downstream processes are tailored to the molecule itself. If the molecules are of a similar type, then the downstream process becomes easy to develop.

In terms of difficulty, the cell lines and expression systems are inherently variable, and clone-to-clone variability adds to the complexity. Scale factors are also more difficult to control in cell culture and fermentation. In general, upstream therefore probably poses a slightly greater challenge, assuming that the molecules are in a given class or category.

Moesta (Bristol-Myers): With today's level of know-how in molecular biology and expression, platform technologies are easier to develop for upstream processes. Identification of a preferred strain or cell line for microbial or mammalian expression, combined with a well-developed expression vector, is the first step in establishing a production platform. This step allows for the use of standardized fermentation or cell-culture conditions requiring limited media and feed optimization. The use of platform expression systems and upstream conditions allow for the generation of significant process experience and forms the basis for developing downstream platforms to the extent possible.

It is easiest to develop a standardized process for initial downstream steps (e.g., centrifugation and depth filtration for cell-culture products). For monoclonal antibodies (mAbs), where the Fc protein domain–Protein A interaction can be exploited to capture the protein from clarified cell-culture broths, additional platform steps are possible (e.g., Protein A-based affinity chromatography and viral inactivation and filtration steps). The final purification steps (i.e., polishing) need to be tailored to the particular antibody at hand and usually require individual optimization. For other proteins, downstream processing becomes less amenable to the platform approach. Individual process steps can be standardized, but will need to be pieced together and optimized on a case-by-case basis.

BMS is developing molecules to which we apply platform-based approaches, including antibodies and adnectins. But even when dealing with well-defined classes of proteins, key challenges for establishing production platforms result from unique properties of individual proteins, such as charge heterogeneity, differences caused by post-translational modifications, and stability. These unique properties can impact both the cell's ability to express a correctly folded and stable protein as well as purification of a homogeneous drug substance.

PharmTech: Could a platform for purification accommodate variations between mAbs? Is it possible to develop a purification platform for various classes of products (e.g., mAbs and enzyme products)?

Atkinson (Cook): Platform purification processes must deal with both process- and product-related impurities. With antibody processes, the process-related impurities tend to dominate the development of the platform. Removal of host cell proteins (HCP), in particular, is usually a primary driver.

For the product-related impurities, most antibody processes are usually dominated by the removal of higher-molecular weight aggregates, followed by clipped forms and other charge variants. This is why so many platforms use an affinity step, followed by some combination of ion-exchange and/or mixed-mode separation.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here